File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: An integrated analysis of phase 2,3 SOF and LDV/SOF trials for the treatment of GT6 HCV Infection

TitleAn integrated analysis of phase 2,3 SOF and LDV/SOF trials for the treatment of GT6 HCV Infection
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2016
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 25th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL 2016), Tokyo, Japan, 20-24 February 2016. In Hepatology International, 2016, v. 10 suppl. 1, p. S8, abstract O-009 How to Cite?
AbstractINTRODUCTION: Chronic HCV infection is endemic in South East Asia with HCV genotype 6 (GT6) accounting for 18–49 % of those infected. Few studies have examined the efficacy and safety of direct acting antiviral (DAA) regimens in GT6 infected patients. The aim of this integrated analysis was to characterize the efficacy and safety of sofosbuvir (SOF)-based regimens in patients with chronicGT6HCVinfection. METHODS: GT6 infected subjects were identified in 5 studies (ATOMIC, NEUTRINO, GS-US-334-0115, ELECTRON2, GS-US-337-0131) and are included in this analysis. Treatment-naı¨ve or treatment-experienced patients received SOF + RBV ± Peg-IFNa or ledipasvir (LDV)/SOF for 12–24 weeks. The primary efficacy endpoint in all studies was SVR12. RESULTS: A total of 52 subjects with GT6 HCV infection were identified. The majority were treatment-naı¨ve (94 %), Asian (81 %), male (58 %), and had IL28B CC alleles (81 %). The mean age was 50 years (range 26–76) and 10 % had cirrhosis. GT6 subtypes included 6a, 6a/b, 6c-1, 6e, 6 g, 6j, 6 l, 6 m, 6o, 6p, 6q, and 6r. One subject in ELECTRON2 withdrew consent after receiving 8 weeks of LDV/SOF and relapsed with the emergent NS5B RAV S282T. All remaining 51 patients achieved SVR12, including 100 % (3/3) experienced and 100 % (5/5) cirrhotics. SVR12/24 results will be presented. CONCLUSIONS: SOF + RBV ± Peg-IFN a and LDV/SOF regimens are well-tolerated and highly effective in patients with chronic GT6 HCV infection including those who are treatment experienced and have compensated cirrhosis. These regimens provide multiple therapeutic options for consideration when evaluating optimal therapy for individual patients with chronic GT6 HCV infection. (Diagram see journal suppl.)
DescriptionOral Presentation: no. O-009
Persistent Identifierhttp://hdl.handle.net/10722/226488
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669

 

DC FieldValueLanguage
dc.contributor.authorLai, CL-
dc.contributor.authorChuang, WL-
dc.contributor.authorHassanein, T-
dc.contributor.authorKowdley, KV-
dc.contributor.authorLawitz, E-
dc.contributor.authorGao, B-
dc.contributor.authorMo, HM-
dc.contributor.authorHyland, R-
dc.contributor.authorYang, JC-
dc.contributor.authorDe-Oertel, S-
dc.contributor.authorNatha, M-
dc.contributor.authorBrainard, D-
dc.contributor.authorKnox, SJ-
dc.contributor.authorMcHutchison, JG-
dc.contributor.authorChan, HLY-
dc.contributor.authorGane, EJ-
dc.date.accessioned2016-06-17T07:44:28Z-
dc.date.available2016-06-17T07:44:28Z-
dc.date.issued2016-
dc.identifier.citationThe 25th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL 2016), Tokyo, Japan, 20-24 February 2016. In Hepatology International, 2016, v. 10 suppl. 1, p. S8, abstract O-009-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/226488-
dc.descriptionOral Presentation: no. O-009-
dc.description.abstractINTRODUCTION: Chronic HCV infection is endemic in South East Asia with HCV genotype 6 (GT6) accounting for 18–49 % of those infected. Few studies have examined the efficacy and safety of direct acting antiviral (DAA) regimens in GT6 infected patients. The aim of this integrated analysis was to characterize the efficacy and safety of sofosbuvir (SOF)-based regimens in patients with chronicGT6HCVinfection. METHODS: GT6 infected subjects were identified in 5 studies (ATOMIC, NEUTRINO, GS-US-334-0115, ELECTRON2, GS-US-337-0131) and are included in this analysis. Treatment-naı¨ve or treatment-experienced patients received SOF + RBV ± Peg-IFNa or ledipasvir (LDV)/SOF for 12–24 weeks. The primary efficacy endpoint in all studies was SVR12. RESULTS: A total of 52 subjects with GT6 HCV infection were identified. The majority were treatment-naı¨ve (94 %), Asian (81 %), male (58 %), and had IL28B CC alleles (81 %). The mean age was 50 years (range 26–76) and 10 % had cirrhosis. GT6 subtypes included 6a, 6a/b, 6c-1, 6e, 6 g, 6j, 6 l, 6 m, 6o, 6p, 6q, and 6r. One subject in ELECTRON2 withdrew consent after receiving 8 weeks of LDV/SOF and relapsed with the emergent NS5B RAV S282T. All remaining 51 patients achieved SVR12, including 100 % (3/3) experienced and 100 % (5/5) cirrhotics. SVR12/24 results will be presented. CONCLUSIONS: SOF + RBV ± Peg-IFN a and LDV/SOF regimens are well-tolerated and highly effective in patients with chronic GT6 HCV infection including those who are treatment experienced and have compensated cirrhosis. These regimens provide multiple therapeutic options for consideration when evaluating optimal therapy for individual patients with chronic GT6 HCV infection. (Diagram see journal suppl.)-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology International-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/[insert DOI]-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleAn integrated analysis of phase 2,3 SOF and LDV/SOF trials for the treatment of GT6 HCV Infection-
dc.typeConference_Paper-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.hkuros258613-
dc.identifier.volume10-
dc.identifier.issuesuppl. 1-
dc.identifier.spageS8, abstract O-009-
dc.identifier.epageS8, abstract O-009-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats